Comments | ECCO Inc.:

Comment

2702

Subject

Name

Mayncnatenq

User

Post

ECCO MEMBER SPOTLIGHT – ARTHUR ALLAIN

Parent Comment

Content

Testimony Before the FDA s Vaccines and Related Biological Products Advisory Committee Regarding Booster Third Doses of the Pfizer-BioNTech COVID-19 Vaccine HRG Publication 2600 In testimony before a meeting of the Food and Drug Administration s FDA s Vaccines and Related Biological Products Advisory Committee, Public Citizen argued that Pfizer and BioNTech have failed to provide sufficient data to assess the risk-benefit profile of a booster third dose of their COVID-19 vaccine in individuals aged 16 or older in the general population. <a href=http://tamoxifenolvadex.com/>nolvadex for gyno</a>

Created

22nd Sep 2022 6:04 am

Modified

22nd Sep 2022 6:04 am

Anguilla

ECCO
P.O. Box CP5380
Sans Soucis
Castries

Tel: 1-758-451-6436/451-6809
Email: ecco@eccorights.org

BVI

ECCO
P.O. Box CP5380
Sans Soucis
Castries

Tel: 1-758-451-6436
Email: ecco@eccorights.org

Dominica

ECCO
McCarthy Marie
P.O. Box
C/o Chez Ophelia
Roseau

Tel: 1-767-448-3438
Email: dominicaagent@eccorights.com

Antigua

ECCO
Head Office
P.O. Box CP5380
Sans Souci
Castries

Tel: 1-758-285-0404
Email: antiguaagent@eccorights.com

Grenada

ECCO
Shrivon Redhead
P.O. Box

St. George's

Tel: 1-473-456-5043
Email: grenadaagent@eccorights.com

Montserrat

ECCO
P.O. Box CP5380
Sans Soucis
Castries

Tel: 1-758-451-6436
Email: ecco@eccorights.org

St Lucia

ECCO
P.O. Box CP5380
Sans Soucis
Castries

Tel: 1-758-451-6436/451-6809
Email: ecco@eccorights.org

St. Kitts and Nevis

ECCO
Grace Richardson
P.O. Box 916

Basseterre

Tel: 1-869-762-7139
Email: st.kittsagent@eccorights.com

St Vincent

ECCO
Dougal Allen
P.O. Box

Kingstown

Tel: 1-784-532-8964
Email: st.vincentagent@eccorights.com

Id: 2702
Subject
Name: Mayncnatenq
User
Post: ECCO MEMBER SPOTLIGHT – ARTHUR ALLAIN
Parent Comment
Content: Testimony Before the FDA s Vaccines and Related Biological Products Advisory Committee Regarding Booster Third Doses of the Pfizer-BioNTech COVID-19 Vaccine HRG Publication 2600 In testimony before a meeting of the Food and Drug Administration s FDA s Vaccines and Related Biological Products Advisory Committee, Public Citizen argued that Pfizer and BioNTech have failed to provide sufficient data to assess the risk-benefit profile of a booster third dose of their COVID-19 vaccine in individuals aged 16 or older in the general population. <a href=http://tamoxifenolvadex.com/>nolvadex for gyno</a>
Created: 22nd Sep 2022 6:04 am
Modified: 22nd Sep 2022 6:04 am

Comment

Actions

Related Comments